Idiopathic pulmonary fibrosis (IPF) is a progressive pulmonary disease leading to death within a few years of diagnosis despite medical therapy. On the basis of methodologies of the Cochrane collaboration, this overview discusses the evidence for IPF therapy. Good-quality studies on oral corticosteroids, the most common medical therapy in use for IPF, are lacking. A few small studies have been carried out on the efficacy of many non-steroid immunosuppressive agents, and the results have been generally disappointing. The most extensively studied medical therapy, gamma interferon, showed a significant effect in a small randomized study, but its efficacy was not confirmed in a larger randomized-controlled trial. The long-awaited good news for patients affected by this deadly disease, and for their physicians, could come in the near future from large randomized-controlled trials with gamma interferon or other immunomodulatory agents.
Luppi, F., Cerri, S., Beghè, B., Fabbri, L., & Richeldi, L. (2004). Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis. RESPIRATORY MEDICINE, 98(11), 1035-1044.
|Citazione:||Luppi, F., Cerri, S., Beghè, B., Fabbri, L., & Richeldi, L. (2004). Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis. RESPIRATORY MEDICINE, 98(11), 1035-1044.|
|Tipo:||Articolo in rivista - Articolo scientifico|
|Carattere della pubblicazione:||Scientifica|
|Presenza di un coautore afferente ad Istituzioni straniere:||No|
|Titolo:||Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis|
|Autori:||Luppi, F; Cerri, S; Beghè, B; Fabbri, L; Richeldi, L|
|Data di pubblicazione:||2004|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/j.rmed.2004.07.019|
|Appare nelle tipologie:||01 - Articolo su rivista|